Answers are grounded in this paper and cite their sources.
Demonstrates cefiderocol's role in reducing inflammation and lung damage in a murine model of acute lung injury, suggesting new treatment avenues.
This study examines the immune-modulatory effects of cefiderocol in a murine model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). Cefiderocol pretreatment significantly reduced lung tissue damage, lowered pro-inflammatory cytokines, and decreased ferroptosis markers. Its protective effect was comparable to that of the ferroptosis inhibitor ferrostatin-1, while cefepime showed limited efficacy. These findings suggest that cefiderocol has an immuno-mediated role in LPS-induced ALI, potentially by modulating ferroptosis and inflammation, warranting further investigation for sepsis-related complications. IMPORTANCE This study examines the immune-modulatory effects of cefiderocol in a murine model of LPS-induced acute lung injury (ALI). Cefiderocol pretreatment significantly reduced lung tissue damage, lowered pro-inflammatory cytokines, and decreased ferroptosis markers. Its protective effect was comparable to that of the ferroptosis inhibitor ferrostatin-1, while cefepime showed limited efficacy. These findings suggest that cefiderocol has an immuno-mediated role in LPS-induced ALI, potentially by modulating ferroptosis and inflammation, warranting further investigation for sepsis-related complications.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: